SE458117B - Penemkarboxylsyraestrar, foerfarande foer framstaellning daerav samt farmaceutiska kompositioner daerav - Google Patents
Penemkarboxylsyraestrar, foerfarande foer framstaellning daerav samt farmaceutiska kompositioner daeravInfo
- Publication number
- SE458117B SE458117B SE8400040A SE8400040A SE458117B SE 458117 B SE458117 B SE 458117B SE 8400040 A SE8400040 A SE 8400040A SE 8400040 A SE8400040 A SE 8400040A SE 458117 B SE458117 B SE 458117B
- Authority
- SE
- Sweden
- Prior art keywords
- penem
- formula
- compound
- acetoxymethyl
- acid ester
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 11
- 239000002253 acid Substances 0.000 title claims description 9
- 150000002148 esters Chemical class 0.000 title claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 31
- -1 Penem carboxylic acid ester Chemical class 0.000 claims description 26
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 4
- 125000005633 phthalidyl group Chemical group 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 239000012430 organic reaction media Substances 0.000 claims description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- FZKGLCPKPZBGLX-ROXVQFJHSA-N acetyloxymethyl (5r,6s)-3-(carbamoyloxymethyl)-6-[(1r)-1-hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate Chemical group S1C(COC(N)=O)=C(C(=O)OCOC(C)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 FZKGLCPKPZBGLX-ROXVQFJHSA-N 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- IKQNRQOUOZJHTR-UHFFFAOYSA-N 3-(carbamoyloxymethyl)-6-(1-hydroxyethyl)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid Chemical compound S1C(COC(N)=O)=C(C(O)=O)N2C(=O)C(C(O)C)C21 IKQNRQOUOZJHTR-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- NHYXMAKLBXBVEO-UHFFFAOYSA-N bromomethyl acetate Chemical compound CC(=O)OCBr NHYXMAKLBXBVEO-UHFFFAOYSA-N 0.000 description 3
- GGRHYQCXXYLUTL-UHFFFAOYSA-N chloromethyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OCCl GGRHYQCXXYLUTL-UHFFFAOYSA-N 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- OOUSUFKQKJONBC-UHFFFAOYSA-N n-(chloromethyl)acetamide Chemical compound CC(=O)NCCl OOUSUFKQKJONBC-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- BIAAQBNMRITRDV-UHFFFAOYSA-N 1-(chloromethoxy)-2-methoxyethane Chemical compound COCCOCCl BIAAQBNMRITRDV-UHFFFAOYSA-N 0.000 description 1
- YJRHGJZKRWGUTB-VFWDIBGWSA-N 2,2-dimethylpropanoyloxymethyl (5R,6S)-3-(carbamoyloxymethyl)-6-[(1R)-1-hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate Chemical compound C(N)(=O)OCC=1S[C@H]2N(C=1C(=O)OCOC(C(C)(C)C)=O)C([C@@H]2[C@@H](C)O)=O YJRHGJZKRWGUTB-VFWDIBGWSA-N 0.000 description 1
- ONIKNECPXCLUHT-UHFFFAOYSA-N 2-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1Cl ONIKNECPXCLUHT-UHFFFAOYSA-N 0.000 description 1
- CLMSHAWYULIVFQ-UHFFFAOYSA-N 3-bromo-3h-2-benzofuran-1-one Chemical compound C1=CC=C2C(Br)OC(=O)C2=C1 CLMSHAWYULIVFQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010056519 Abdominal infection Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 201000004813 Bronchopneumonia Diseases 0.000 description 1
- YKPQQNQROSEMFQ-ROXVQFJHSA-N C(C)(=O)NCOC(=O)C1=C(S[C@H]2N1C([C@@H]2[C@@H](C)O)=O)COC(N)=O Chemical compound C(C)(=O)NCOC(=O)C1=C(S[C@H]2N1C([C@@H]2[C@@H](C)O)=O)COC(N)=O YKPQQNQROSEMFQ-ROXVQFJHSA-N 0.000 description 1
- PIWJFCFHQLEBSJ-VFWDIBGWSA-N C(N)(=O)OCC=1S[C@H]2N(C1C(=O)OCOCCOC)C([C@@H]2[C@@H](C)O)=O Chemical compound C(N)(=O)OCC=1S[C@H]2N(C1C(=O)OCOCCOC)C([C@@H]2[C@@H](C)O)=O PIWJFCFHQLEBSJ-VFWDIBGWSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 101100024779 Caenorhabditis elegans mua-3 gene Proteins 0.000 description 1
- 101100135744 Caenorhabditis elegans pch-2 gene Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 101100353161 Drosophila melanogaster prel gene Proteins 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010061977 Genital infection female Diseases 0.000 description 1
- 206010056523 Hepatobiliary infection Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 101150093411 ZNF143 gene Proteins 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- 125000001539 acetonyl group Chemical group [H]C([H])([H])C(=O)C([H])([H])* 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- TYOQLJHWYCTPCB-RCAYSMOQSA-N benzamidomethyl (5R,6S)-3-(carbamoyloxymethyl)-6-[(1R)-1-hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate Chemical compound C(C1=CC=CC=C1)(=O)NCOC(=O)C1=C(S[C@H]2N1C([C@@H]2[C@@H](C)O)=O)COC(N)=O TYOQLJHWYCTPCB-RCAYSMOQSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000012455 bioassay technique Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- JAMFGQBENKSWOF-UHFFFAOYSA-N bromo(methoxy)methane Chemical compound COCBr JAMFGQBENKSWOF-UHFFFAOYSA-N 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- ZYZWOSIRFVIBRH-UHFFFAOYSA-N chloroform;cyclohexane Chemical compound ClC(Cl)Cl.C1CCCCC1 ZYZWOSIRFVIBRH-UHFFFAOYSA-N 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000005027 hydroxyaryl group Chemical group 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- CIUJQWLLGXKZQD-UHFFFAOYSA-N n-(chloromethyl)benzamide Chemical compound ClCNC(=O)C1=CC=CC=C1 CIUJQWLLGXKZQD-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000012048 reactive intermediate Substances 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D499/86—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with only atoms other than nitrogen atoms directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D499/88—Compounds with a double bond between positions 2 and 3 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB838300295A GB8300295D0 (en) | 1983-01-06 | 1983-01-06 | Penem esters |
Publications (3)
Publication Number | Publication Date |
---|---|
SE8400040D0 SE8400040D0 (sv) | 1984-01-04 |
SE8400040L SE8400040L (sv) | 1984-07-07 |
SE458117B true SE458117B (sv) | 1989-02-27 |
Family
ID=10535987
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE8400040A SE458117B (sv) | 1983-01-06 | 1984-01-04 | Penemkarboxylsyraestrar, foerfarande foer framstaellning daerav samt farmaceutiska kompositioner daerav |
Country Status (31)
Country | Link |
---|---|
US (1) | US5051416A (es) |
JP (1) | JPS59134795A (es) |
KR (1) | KR900004418B1 (es) |
AT (1) | AT382622B (es) |
AU (1) | AU557178B2 (es) |
BE (1) | BE898603A (es) |
CA (1) | CA1215042A (es) |
CH (1) | CH659073A5 (es) |
CS (2) | CS235996B2 (es) |
DE (1) | DE3400090A1 (es) |
DK (1) | DK166387C (es) |
ES (1) | ES528546A0 (es) |
FI (1) | FI81103C (es) |
FR (1) | FR2539130B1 (es) |
GB (2) | GB8300295D0 (es) |
GR (1) | GR81730B (es) |
HK (1) | HK74987A (es) |
HU (1) | HU191243B (es) |
IE (1) | IE56903B1 (es) |
IL (1) | IL70606A (es) |
IT (1) | IT1209490B (es) |
NL (1) | NL8400015A (es) |
NO (1) | NO160446C (es) |
NZ (1) | NZ206743A (es) |
PH (1) | PH18881A (es) |
PT (1) | PT77922B (es) |
SE (1) | SE458117B (es) |
SG (1) | SG34387G (es) |
SU (1) | SU1209031A3 (es) |
UA (1) | UA6039A1 (es) |
ZA (1) | ZA8457B (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2206578B (en) * | 1987-07-07 | 1991-07-03 | Erba Carlo Spa | Process for the preparation of penems |
US5364768A (en) * | 1987-07-07 | 1994-11-15 | Farmitalia Carlo Erba S.R.L. | Process for the preparation of penems |
EP0567949B1 (en) | 1992-04-28 | 2001-02-21 | Tanabe Seiyaku Co., Ltd. | Method for removing silyl protecting groups for hydroxy group |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL7401782A (es) * | 1973-02-14 | 1974-08-16 | ||
GB2043639B (en) * | 1979-02-24 | 1983-07-20 | Erba Farmitalia | 3-optionally substituted methyl-2-penem derivatives |
ZA80993B (en) * | 1979-02-24 | 1981-02-25 | Erba Farmitalia | -lactam-containing antibacterial agents and -lactamase inhibitors and preparation thereof |
GB2043699B (en) * | 1979-03-03 | 1983-05-11 | Park Chem Co | Cyanide-free carburizing process and composition |
US4482565A (en) * | 1980-02-22 | 1984-11-13 | Farmitalia Carlo Erba S.P.A. | β-Lactam-containing antibacterial agents and β-lactamase inhibitors |
AT379399B (de) * | 1981-12-11 | 1985-12-27 | Erba Farmitalia | Verfahren zur herstellung von optisch aktiven penemen |
-
1983
- 1983-01-06 GB GB838300295A patent/GB8300295D0/en active Pending
- 1983-12-29 ES ES528546A patent/ES528546A0/es active Granted
-
1984
- 1984-01-02 FI FI840003A patent/FI81103C/fi not_active IP Right Cessation
- 1984-01-03 AU AU23047/84A patent/AU557178B2/en not_active Ceased
- 1984-01-03 AT AT0001584A patent/AT382622B/de not_active IP Right Cessation
- 1984-01-03 GB GB08400043A patent/GB2133010B/en not_active Expired
- 1984-01-03 DE DE19843400090 patent/DE3400090A1/de not_active Ceased
- 1984-01-03 GR GR73420A patent/GR81730B/el unknown
- 1984-01-03 NL NL8400015A patent/NL8400015A/nl not_active Application Discontinuation
- 1984-01-03 IT IT8419007A patent/IT1209490B/it active
- 1984-01-03 IL IL70606A patent/IL70606A/xx not_active IP Right Cessation
- 1984-01-03 CS CS8480A patent/CS235996B2/cs unknown
- 1984-01-03 FR FR8400040A patent/FR2539130B1/fr not_active Expired
- 1984-01-04 ZA ZA8457A patent/ZA8457B/xx unknown
- 1984-01-04 PH PH30064A patent/PH18881A/en unknown
- 1984-01-04 SE SE8400040A patent/SE458117B/sv not_active IP Right Cessation
- 1984-01-04 PT PT77922A patent/PT77922B/pt not_active IP Right Cessation
- 1984-01-04 CA CA000444654A patent/CA1215042A/en not_active Expired
- 1984-01-04 BE BE0/212151A patent/BE898603A/fr not_active IP Right Cessation
- 1984-01-04 IE IE6/84A patent/IE56903B1/en not_active IP Right Cessation
- 1984-01-05 SU SU843688716A patent/SU1209031A3/ru active
- 1984-01-05 HU HU8437A patent/HU191243B/hu not_active IP Right Cessation
- 1984-01-05 DK DK005284A patent/DK166387C/da active
- 1984-01-05 UA UA3688716A patent/UA6039A1/uk unknown
- 1984-01-05 JP JP59000110A patent/JPS59134795A/ja active Granted
- 1984-01-05 NZ NZ206743A patent/NZ206743A/en unknown
- 1984-01-05 KR KR1019840000014A patent/KR900004418B1/ko not_active IP Right Cessation
- 1984-01-05 CH CH42/84A patent/CH659073A5/de not_active IP Right Cessation
- 1984-01-05 NO NO840035A patent/NO160446C/no unknown
-
1987
- 1987-04-14 SG SG34387A patent/SG34387G/en unknown
- 1987-10-15 HK HK749/87A patent/HK74987A/xx not_active IP Right Cessation
-
1989
- 1989-04-03 US US07/331,853 patent/US5051416A/en not_active Expired - Fee Related
-
1991
- 1991-12-20 CS CS914150A patent/CS415091A3/cs unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4342772A (en) | β-Lactam compounds, antibacterial compositions thereof and method of use | |
US4168314A (en) | 6-(1'-Hydroxyethyl)-2-aminoethylthio-pen-2-em-3-carboxylic acid | |
DE2837264C2 (es) | ||
CH632513A5 (de) | Verfahren zur herstellung von ungesaettigten derivaten der 7-acylamido-3-cephem-4-carbonsaeure. | |
SE452465B (sv) | 6 beta-halopenicillansyraderivat och kompositioner innehallande desamma | |
EP0163190A2 (de) | Beta-Lactamantibiotika, Verfahren zu deren Herstellung sowie ihre Verwendung als Arzneimittel oder Wachstumsförderer in der Tieraufzucht oder als Antioxidantien | |
DE3345989A1 (de) | Fluormethylthiooxacephalosporine, verfahren zu ihrer herstellung und ihre verwendung | |
KR0178956B1 (ko) | 항균성 페넴 에스테르 유도체 | |
SE458117B (sv) | Penemkarboxylsyraestrar, foerfarande foer framstaellning daerav samt farmaceutiska kompositioner daerav | |
EP0162394B1 (de) | Neue Cephalosporine und Verfahren zu ihrer Herstellung | |
KR0178957B1 (ko) | 페넴 화합물 | |
EP0192176A2 (de) | Neue Cephalosporine, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimitteln | |
GB2127825A (en) | Vinylthioacetamido oxacephalosporin derivatives and intermediates therefor | |
SU1015830A3 (ru) | Способ получени сложных эфиров 6-амидинопенициллановых кислот или их аддитивных солей с кислотами и его вариант | |
US3274175A (en) | Penicillin derivatives | |
FR2553418A1 (fr) | Derives d'acides (oxo carbonamido heterocyclique) cephem carboxyliques a proprietes antibacteriennes | |
KR0177844B1 (ko) | 항균성 페넴화합물 | |
EP0379132A2 (de) | Cephalosporinderivate und Verfahren zu ihrer Herstellung | |
US4081441A (en) | Antibacterial agents | |
DE2818985C2 (de) | Halogenarylmalonamidooxacephalosporine und deren Verwendung bei der Bekämpfung bakterieller Infektionen | |
US4407751A (en) | Processes for preparing β-lactams | |
DE2852745A1 (de) | Neue penicillin- und cephalosporinderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel | |
NZ199129A (en) | Cephalosporin derivatives and pharmaceutical compositions | |
EP0049814A2 (de) | Neue Cephalosporine, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
EP0390066A2 (de) | Cephalosporinderivate und Verfahren zu ihrer Herstellung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NAL | Patent in force |
Ref document number: 8400040-5 Format of ref document f/p: F |
|
NUG | Patent has lapsed |